Trigeminal Neuralgia Market

• The treatment of trigeminal neuralgia consists of surgical treatment, Rhizotomy, Microvascular Decompression surgery, Stereotactic Radiosurgery.
• Anticonvulsant is mainly used as the first-line treatment for trigeminal neuralgia. Anticonvulsants can also help reduce nerve sensitivity and control pain attacks. Additionally, antispasmodic medications are available to alleviate muscle spasms that may trigger trigeminal pain episodes.
• The antiepileptic drugs carbamazepine and oxcarbazepine are the first-line pharmacological treatment for trigeminal neuralgia. 
• Surgery is a treatment option for trigeminal neuralgia that does not respond well to other treatment methods. Surgical intervention depends on factors such as the severity of symptoms, response to previous treatments, and the patient’s overall health condition.
• Microvascular decompression is the most successful trigeminal neuralgia surgery. About two-thirds of people experience permanent relief; others remain pain-free for many years. 
• The rate of trigeminal neuralgia is higher among multiple sclerosis patients than in the general population; about 2% of all people with trigeminal neuralgia have multiple sclerosis.
• Several drugs approved for other indications–like epilepsy or neuropathic pain–have been used off-label or are recognized in clinical guidelines as first-line treatments for trigeminal neuralgia. These include carbamazepine, which has been shown to be effective in reducing paroxysmal facial pain, and oxcarbazepine, which has been used off-label because of a better tolerability profile than carbamazepine.
• The emerging pipeline for trigeminal neuralgia remains limited, with therapies like— Basimglurant [NOE-101], SR750 and others which are currently in the later phases of clinical trial. The pharmaceutical companies involved in its development are Noema Pharma, SIMR Biotechnology and others respectively.

DelveInsight's “Trigeminal neuralgia – Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of trigeminal neuralgia epidemiology, market, and clinical development in trigeminal neuralgia. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the trigeminal neuralgia market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.

Trigeminal neuralgia market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted trigeminal neuralgia market size from 2020 to 2034 in 7MM. The report also covers current trigeminal neuralgia treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Trigeminal neuralgia Understanding and Treatment Algorithm

Trigeminal neuralgia Overview 

The persistent pain disorder known as trigeminal neuralgia (TN) is brought on by compression of the trigeminal nerve as it enters the brainstem, frequently by a blood vessel. Multiple sclerosis, tumours, and occasionally nerve trauma or injury are other causes. When trigeminal neuralgia is brought on by another illness or issue, such as a tumour, cyst, or arteriovenous malformation, face trauma, etc., it is referred to as secondary trigeminal neuralgia. Although trigeminal neuralgia is not fatal, it can change a person's life. Because even seemingly insignificant tasks like chewing, speaking, smiling, and cleaning your teeth can cause sudden, severe pain, TN is a physical and psychological disorder. Another name for trigeminal neuralgia is tic douloureux, which means "painful tic."

Trigeminal neuralgia Diagnosis

Physical and neurological examinations are typically used to diagnose trigeminal neuralgia. A number of factors, including the type of pain experienced, the location of the pain, and the cause of the painful episode, are taken into account for the diagnosis. Facial pain is frequently the most common symptom that a doctor determines. To determine the precise reason for trigeminal neuralgia discomfort, such as tumour pressure or blood vessel pressure, the doctor may also suggest a brain MRI.

 Further details related to country-based variations in diagnosis are provided in the report.

Trigeminal neuralgia Treatment

The treatment of Trigeminal neuralgia often starts with medication as the first therapy that doctors recommend for primary (classic) and idiopathic TN. The anti-convulsant most commonly prescribed and the only FDA-approved therapy for trigeminal neuralgia is TEGRETOL (carbamazepine), which provides at least partial pain relief. Anticonvulsants are used as initial treatment for trigeminal neuralgia and also help reduce nerve sensitivity and control pain attacks. Additionally, antispasmodic medications are available to alleviate muscle spasms that may trigger trigeminal pain episodes. The antiepileptic drugs carbamazepine and oxcarbazepine are the first-line pharmacological treatment for trigeminal neuralgia. 

Surgical options are also there, which can be both invasive and non-invasive. Acupuncture has been shown to help reduce the intensity and/or frequency of flare-ups in trigeminal neuralgia, offering a complementary treatment option for some patients.

Trigeminal neuralgia Epidemiology

The trigeminal neuralgia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total incidence cases of trigeminal neuralgia, age-specific incident cases of trigeminal neuralgia, and gender-specific incident cases of trigeminal neuralgia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034. 

• Among the 7MM, the United States had the highest market share of trigeminal neuralgia in 2024.
• As per the secondary search, Women are more commonly affected than men. 
• Most cases of trigeminal neuralgia occur after age 50, but the disease can be occur in the second and third decades of life; trigeminal neuralgia is rarely diagnosed in childhood.
• Approximately 10,000–15,000 new cases occur each year in the United States.
• Trigeminal neuralgia was most frequently right-sided (59%) and limited to one cranial nerve V-branch, of which V2 was the most common. 

Trigeminal neuralgia Recent Developments

• In August 2025, NeuroOne Medical Technologies Corporation announced that the FDA cleared its OneRF® Trigeminal Nerve Ablation System for creating radiofrequency lesions to treat pain or for functional neurosurgical procedures, with a limited commercial launch planned for Q4 2025.

Trigeminal neuralgia Drug Chapters

The drug chapter segment of the Trigeminal neuralgia report encloses a detailed analysis of trigeminal neuralgia marketed drugs and emerging pipeline drugs. It also deep dives into Trigeminal neuralgia’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Marketed Drugs

TEGRETOL (carbamazepine): Novartis

TEGRETOL is an anticonvulsant and specific analgesic for trigeminal neuralgia, available for oral administration as chewable tablets. It was initially approved for the treatment of epilepsy, and later it was also approved for the treatment of trigeminal neuralgia and other neurological conditions. Several pharmaceutical companies have received approval for their generic version of TEGRETOL, but the drug was originally developed and marketed by Novartis for treating epilepsy and trigeminal neuralgia.

In the US, carbamazepine won initial approval by the FDA for the treatment of trigeminal neuralgia in 1968. 

Emerging Drugs

Basimglurant (NOE-101): Noema Pharma

Basimglurant is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5), which is overexpressed in chronic pain. In October 2022, the US FDA granted Fast Track Designation (FTD) to basimglurant for the treatment of trigeminal neuralgia. Currently, the drug is being evaluated in Phase II/III for the management of pain associated with trigeminal neuralgia.

In December 2024, Noema Pharma announced the successful completion of a Series B extension financing round, raising CHF 130 million with investment from EQT Life Sciences. The new funding will support Noema Pharma’s four active Phase II trials, with key data readouts expected in 2025. This includes the development of basimglurant for severe pain in trigeminal neuralgia, seizures in tuberous sclerosis complex, gemlapodect for Tourette syndrome and childhood-onset fluency disorder, and NOE-115 for vasomotor symptoms and other menopause-related symptoms.

SR750: SIMR Biotechnology

SR750 is a first-in-class small molecule with a novel mechanism of action targeting neuropathic pain pathways. Developed by SIMR Biotechnology, SR750 offers a new approach to treating trigeminal neuralgia by targeting pain sensitization caused by trigeminal nerve root injury while avoiding central nervous system side effects, making it a potential new therapeutic option for this condition. The drug has been granted Orphan Drug Designation (ODD) by the US FDA. This drug is currently in a Phase II clinical trial.

In September 2024, SIMR Biotech announced the enrollment of the first patient in its Phase II clinical trial of SR750 for the treatment of trigeminal neuralgia.

Note: Detailed therapy assessment will be provided in the full report of trigeminal neuralgia

Drug Class Insights

Anticonvulsant

As of right now, the only medication available for treating trigeminal neuralgia is TEGRETOL. As an anticonvulsant, carbamazepine is a derivative of dibenzoazepine carboxamide that shares structural similarities with tricyclic antidepressants. It is mostly used to treat trigeminal neuralgia, acute manic or mixed episodes in bipolar illness, and epilepsy, especially partial and generalised tonic-clonic seizures. By preventing the brain's voltage-gated sodium channels from opening, it stabilises hyperactive neuronal membranes and lessens aberrant electrical activity. Over time, TEGRETOL speeds up its metabolism due to a process known as enzyme autoinduction. This comes in chewable tablet, oral suspension, and immediate and extended-release tablet form.

Metabotropic glutamate receptor 5 (mGluR5)

The brain's main excitatory neurotransmitter, glutamate, activates the G-protein-coupled metabotropic glutamate receptor 5 (mGluR5), which is a member of Group I metabotropic glutamate receptors. It is mainly linked to Gq/11 proteins, which cause phospholipase C (PLC) to become active. This results in the synthesis of IP₃ and DAG, elevated intracellular calcium levels, and protein kinase C (PKC) activation. Because of its high expression in brain regions such as the hippocampus, striatum, cortex, and amygdala, mGluR5 is crucial for learning, memory, emotion, and motor control. Metabotropic glutamate receptor 5 (mGluR5) is not yet recognised for the treatment of trigeminal neuralgia; nonetheless, preclinical research suggests that it may have theoretical or emergent significance.

Trigeminal neuralgia Market Outlook

Treatment options include the anti-convulsant most commonly prescribed and FDA-approved for trigeminal neuralgia is TEGRETOL (carbamazepine), which provides at least partial pain relief for 80 to 90% of patients. The muscle relaxant baclofen may also be prescribed, either alone or in combination with other medications.

If medications have proven ineffective in treating trigeminal neuralgia, several surgical procedures may help control the pain.

Rhizotomy is a minimally invasive surgical procedure to remove sensation from a painful nerve by killing nerve fibers responsible for sending pain signals to the brain. Microvascular decompression surgery is regarded as the most long-lasting treatment for trigeminal neuralgia caused by blood vessel compression, and it helps about 80% of people with this diagnosis. Stereotactic radiosurgery, sometimes known as CyberKnife or Gamma Knife treatment, is another outpatient procedure that can be used to treat trigeminal neuralgia. This procedure is painless and is performed without anesthesia. Close to 70% of patients experience significant pain relief within weeks of undergoing stereotactic radiosurgery.

Drugs in the pipeline for trigeminal neuralgia remains limited, few drugs such as Basimglurant ([NOE-101] Noema Pharma), SR750 (Shanghai SIMR Biotechnology), and KRIYA-748 (Kriya Therapeutics) is currently being developed in different stages of clinical development.

Trigeminal neuralgia drug uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies' drug uptake in the report…

Trigeminal neuralgia Pipeline Development Activities

The report provides insights into different therapeutic candidates in the marketed and emerging stages. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Trigeminal neuralgia therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Weser-Egge Hospital, Johns Hopkins University School of Medicine, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or trigeminal neuralgia market trends. 

Qualitative Analysis

We perform qualitative and market intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyses multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyse the effectiveness of therapy.

The analyst analyses multiple emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry.

In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of Trigeminal neuralgia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Trigeminal neuralgia market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Trigeminal neuralgia market.

Trigeminal neuralgia Report Insights

• Patient Population
• Therapeutic Approaches
• Trigeminal neuralgia Pipeline Analysis
• Trigeminal neuralgia Market Size and Trends
• Existing and Future Market Opportunity 

Trigeminal neuralgia Report Key Strengths

• Ten-Year Forecast
• 7MM Coverage 
• Trigeminal neuralgia Epidemiology Segmentation
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Trigeminal neuralgia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

FAQs

• What was the trigeminal neuralgia total market size, the market size by therapies, market share (%) distribution in 2024, and what would it look like in 2034? What are the contributing factors for this growth?
• At what CAGR, the trigeminal neuralgia market is expected to grow at the 7MM level during the study period (2020–2034)?
• How is the United States’ trigeminal neuralgia competitive landscape evolving? 
• How will upcoming emerging therapies will going to impact the current market share?
• What are the disease risks, burdens, and unmet needs of TRIGEMINAL NEURALGIA? 
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Trigeminal neuralgia?
• What is the historical and forecasted Trigeminal neuralgia patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• How are emerging therapies performing on parameters like efficacy, safety, route of administration (RoA), trigeminal neuralgia treatment duration, and frequencies on the basis of their clinical trial results?
• What are the current options for the treatment of trigeminal neuralgia? What are the current treatment guidelines for the treatment of trigeminal neuralgia in the US and Europe?
• How many are emerging therapies in the mid and late-stage of development for trigeminal neuralgia treatment?
• What key designations have been granted for the emerging therapies for trigeminal neuralgia?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the trigeminal neuralgia market.
• Insights on patient share/disease burden, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand KOLs’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.